FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

OMB APPROVAL OMB 3235-Number: 0104 Estimated average burden hours per 0.5 response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
1. Name and Address of Reporting	2. Date	2. Date of Event Requiring			3. Issuer Name and Ticker or Trading Symbol				
Person *	Statem		REXAHN	REXAHN PHARMACEUTICALS, INC. [RNN]					
Price Ben Gil	,	h/Day/Year)						
(Last) (First) (Middle)	11/29	/2018		4. Relationsl	nin o	of Reporting	5 If Am	endment, Date Original	
C/O REXAHN				Person(s) to				Filed(Month/Day/Year)	
PHARMACEUTICALS,			· /		applicable)	1 110 G(W	1 110 d (110 mus 2 d), 1 out)		
INC., 15245 SHADY GROVE			_X_ Director	X_ Director 10% Owner Officer (give Other (specify					
ROAD, SUITE 455			Officer (g						
· · · · · · · · · · · · · · · · · · ·				title below)		ociow)			
(Street)								dual or Joint/Group	
DOGUMENT NO 20050							•	neck Applicable Line) filed by One Reporting Person	
ROCKVILLE, MD 20850								iled by More than One Reporting	
							Person		
(City) (State) (Zip)		Tal	ble I	- Non-Derivat	ive	Securities	Beneficially	Owned	
1.Title of Security		2. A	mour	nt of Securities	3.		. Nature of Inc	lirect Beneficial	
(Instr. 4)		Ben	eficia	lly Owned		•	Ownership	*	
		(Ins	tr. 4)			rm: Direct (Instr. 5)		
) or			
						direct (I)			
					(In	str. 5)			
Reminder: Report on a separate line f	or each clas	s of securit	iec he	neficially owned	dired	etly or indire	otly	SEC 1473 (7-02)	
				n of informatio		~	•		
				m displays a c					
number.	o respond	เ นเแฮออ แ	16 101	iii uispiays a c	uiit	entry vanu	OWID COILLO		
indiliber.									
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security	2. Date Exe	rcisable	3. Ti	tle and Amount o	f	4.	5.	6. Nature of Indirect	
(Instr. 4)	and Expirati	ion Date	Secu	rities Underlying		Conversion	Ownership	Beneficial Ownership	
			vative Security	Price of De		Form of	(Instr. 5)		
			r. 4)			Derivative			
I	Date	Expiration				Derivative	Security:		
I	Exercisable	•		Amount or Numb	her	Security	Direct (D)		
			Title	of Shares			or Indirect		
							(I) (Instr. 5)		
							(Ilisti. 3)		
Reporting Owners									

Reporting Owner Name / Address		Relationships				
		10% Owner	Officer	Other		
Price Ben Gil C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X					

Signatures

,	/s/ Douglas J. Swirsky, as attorney-in-fact for Ben Gil Price		12/03/2018
_	**Signature of Reporting Person		Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit List-Exhibit 24 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

REXAHN PHARMACEUTICALS, INC.

SECTION 16 POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints the Chief Executive Officer and the President and Chief Financial Officer of Rexahn Pharmaceuticals, Inc. (the "Company"), and each of them, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder:
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of November 2018.

/s/ Ben Gil Price	
Ben Gil Price	